Trial: 201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors

Phase

I

Principal Investigator

Adkins, Douglas

Disease Site

Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Urinary; Prostate; Urinary Bladder

Learn more about this study at: clinicaltrials.gov